{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:18:11Z","timestamp":1791310691164,"version":"4.3.1"},"reference-count":20,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2010,7,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> For several decades, the treatment of elderly patients with multiple myeloma (MM) has consisted of melphalan and prednisone (MP). The Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON) investigated the efficacy of thalidomide added to MP (MP-T) in a randomized phase III trial. The objective of this study was to investigate the efficacy, toxicity, and effects on quality of life of MP-T. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> A randomized phase III trial compared standard MP with MP-T (thalidomide 200 mg\/d) in newly diagnosed patients with multiple myeloma older than age 65 years. Maintenance therapy with thalidomide 50 mg\/d was administered to patients after MP-T until relapse. The primary end point was event-free survival (EFS); response rate, overall survival (OS), and progression-free survival (PFS) were secondary end points. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> An intent-to-treat analysis of 333 evaluable patients showed significantly higher response rates in MP-T\u2013treated patients compared with MP-treated patients a response (\u2265 partial response: 66% v 45%, respectively; P &lt; .001; and \u2265 very good partial response [VGPR]: 27% v 10%, respectively; P &lt; .001). EFS was 13 months with MP-T versus 9 months with MP (P &lt; .001). OS was 40 months with MP-T versus 31 months with MP (P = .05). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> This study demonstrates that thalidomide improves the response rate and VGPR in elderly patients with newly diagnosed MM. MP-T also results in a better EFS, PFS, and OS. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2009.26.1610","type":"journal-article","created":{"date-parts":[[2010,6,2]],"date-time":"2010-06-02T01:53:40Z","timestamp":1275443620000},"page":"3160-3166","source":"Crossref","is-referenced-by-count":221,"title":["Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study"],"prefix":"10.1200","volume":"28","author":[{"given":"Pierre","family":"Wijermans","sequence":"first","affiliation":[{"name":"From the Haga Hospital, the Hague; MST Twente, Enschede; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) Data Center, Erasmus Medical Center, Rotterdam; Meander Hospital, Amersfoort; Jeroen Bosch Hospital, 's Hertogenbosch; VU Medisch Centrum, Amsterdam; Isala Hospital, Zwolle; Diaconessen Hospital; and Universitair Medisch Centrum Utrecht, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Schaafsma","sequence":"additional","affiliation":[{"name":"From the Haga Hospital, the Hague; MST Twente, Enschede; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) Data Center, Erasmus Medical Center, Rotterdam; Meander Hospital, Amersfoort; Jeroen Bosch Hospital, 's Hertogenbosch; VU Medisch Centrum, Amsterdam; Isala Hospital, Zwolle; Diaconessen Hospital; and Universitair Medisch Centrum Utrecht, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Termorshuizen","sequence":"additional","affiliation":[{"name":"From the Haga Hospital, the Hague; MST Twente, Enschede; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) Data Center, Erasmus Medical Center, Rotterdam; Meander Hospital, Amersfoort; Jeroen Bosch Hospital, 's Hertogenbosch; VU Medisch Centrum, Amsterdam; Isala Hospital, Zwolle; Diaconessen Hospital; and Universitair Medisch Centrum Utrecht, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne","family":"Ammerlaan","sequence":"additional","affiliation":[{"name":"From the Haga Hospital, the Hague; MST Twente, Enschede; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) Data Center, Erasmus Medical Center, Rotterdam; Meander Hospital, Amersfoort; Jeroen Bosch Hospital, 's Hertogenbosch; VU Medisch Centrum, Amsterdam; Isala Hospital, Zwolle; Diaconessen Hospital; and Universitair Medisch Centrum Utrecht, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulamiet","family":"Wittebol","sequence":"additional","affiliation":[{"name":"From the Haga Hospital, the Hague; MST Twente, Enschede; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) Data Center, Erasmus Medical Center, Rotterdam; Meander Hospital, Amersfoort; Jeroen Bosch Hospital, 's Hertogenbosch; VU Medisch Centrum, Amsterdam; Isala Hospital, Zwolle; Diaconessen Hospital; and Universitair Medisch Centrum Utrecht, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"Sinnige","sequence":"additional","affiliation":[{"name":"From the Haga Hospital, the Hague; MST Twente, Enschede; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) Data Center, Erasmus Medical Center, Rotterdam; Meander Hospital, Amersfoort; Jeroen Bosch Hospital, 's Hertogenbosch; VU Medisch Centrum, Amsterdam; Isala Hospital, Zwolle; Diaconessen Hospital; and Universitair Medisch Centrum Utrecht, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"From the Haga Hospital, the Hague; MST Twente, Enschede; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) Data Center, Erasmus Medical Center, Rotterdam; Meander Hospital, Amersfoort; Jeroen Bosch Hospital, 's Hertogenbosch; VU Medisch Centrum, Amsterdam; Isala Hospital, Zwolle; Diaconessen Hospital; and Universitair Medisch Centrum Utrecht, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinus","family":"van Marwijk Kooy","sequence":"additional","affiliation":[{"name":"From the Haga Hospital, the Hague; MST Twente, Enschede; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) Data Center, Erasmus Medical Center, Rotterdam; Meander Hospital, Amersfoort; Jeroen Bosch Hospital, 's Hertogenbosch; VU Medisch Centrum, Amsterdam; Isala Hospital, Zwolle; Diaconessen Hospital; and Universitair Medisch Centrum Utrecht, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"van der Griend","sequence":"additional","affiliation":[{"name":"From the Haga Hospital, the Hague; MST Twente, Enschede; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) Data Center, Erasmus Medical Center, Rotterdam; Meander Hospital, Amersfoort; Jeroen Bosch Hospital, 's Hertogenbosch; VU Medisch Centrum, Amsterdam; Isala Hospital, Zwolle; Diaconessen Hospital; and Universitair Medisch Centrum Utrecht, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"Lokhorst","sequence":"additional","affiliation":[{"name":"From the Haga Hospital, the Hague; MST Twente, Enschede; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) Data Center, Erasmus Medical Center, Rotterdam; Meander Hospital, Amersfoort; Jeroen Bosch Hospital, 's Hertogenbosch; VU Medisch Centrum, Amsterdam; Isala Hospital, Zwolle; Diaconessen Hospital; and Universitair Medisch Centrum Utrecht, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"From the Haga Hospital, the Hague; MST Twente, Enschede; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) Data Center, Erasmus Medical Center, Rotterdam; Meander Hospital, Amersfoort; Jeroen Bosch Hospital, 's Hertogenbosch; VU Medisch Centrum, Amsterdam; Isala Hospital, Zwolle; Diaconessen Hospital; and Universitair Medisch Centrum Utrecht, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","first-page":"3832","volume":"12","author":"Myeloma Trialists' Collaborative Group","year":"1998","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02857.x"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0221"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.8851"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402866"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68338-4"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61537-2"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403533"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008890401133"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.0948"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.78.78"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-149427"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-145235"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222539"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-169565"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/10428190601186168"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022962"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.8573"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2009.26.1610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T23:42:05Z","timestamp":1653522125000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2009.26.1610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,1]]},"references-count":20,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2010,7,1]]}},"alternative-id":["10.1200\/JCO.2009.26.1610"],"URL":"https:\/\/doi.org\/10.1200\/jco.2009.26.1610","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,1]]}}}